These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 15160284)

  • 1. Pharmacokinetic linearity of i.v. vinorelbine from an intra-patient dose escalation study design.
    Khayat D; Rixe O; Brunet R; Goupil A; Bugat R; Harousseau JL; Ifrah N; Puozzo C
    Cancer Chemother Pharmacol; 2004 Sep; 54(3):193-205. PubMed ID: 15160284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral versus intravenous vinorelbine: clinical safety profile.
    Gebbia V; Puozzo C
    Expert Opin Drug Saf; 2005 Sep; 4(5):915-28. PubMed ID: 16111453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bayesian estimate of vinorelbine pharmacokinetic parameters in elderly patients with advanced metastatic cancer.
    Gauvin A; Pinguet F; Culine S; Astre C; Gomeni R; Bressolle F
    Clin Cancer Res; 2000 Jul; 6(7):2690-5. PubMed ID: 10914711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A simultaneous oral/intravenous population pharmacokinetic model for vinorelbine.
    Variol P; Nguyen L; Tranchand B; Puozzo C
    Eur J Clin Pharmacol; 2002 Oct; 58(7):467-76. PubMed ID: 12389069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of oral versus intravenous dose of vinorelbine to achieve equivalent blood exposures in patients with solid tumours.
    Bourgeois H; Vermorken J; Dark G; Jones A; Fumoleau P; Stupp R; Tourani J; Brain E; Nguyen L; Lefresne F; Puozzo C
    Cancer Chemother Pharmacol; 2007 Aug; 60(3):407-13. PubMed ID: 17541591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-small-cell lung cancer in elderly patients: influence of age on vinorelbine oral pharmacokinetics.
    Puozzo C; Gridelli C
    Clin Lung Cancer; 2004 Jan; 5(4):237-42. PubMed ID: 14967076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mild to moderate liver dysfunction does not require dose reduction of oral or intravenous vinorelbine: results of a pharmacokinetic study.
    Kitzen JJ; Puozzo C; de Jonge MJ; Brandely M; Verweij J
    Eur J Cancer; 2010 Jan; 46(2):266-9. PubMed ID: 19944596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vinorelbine and low-dose cyclophosphamide in the treatment of pediatric sarcomas: pilot study for the upcoming European Rhabdomyosarcoma Protocol.
    Casanova M; Ferrari A; Bisogno G; Merks JH; De Salvo GL; Meazza C; Tettoni K; Provenzi M; Mazzarino I; Carli M
    Cancer; 2004 Oct; 101(7):1664-71. PubMed ID: 15378498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetics of short intravenous vinorelbine infusions in patients with metastatic breast cancer.
    Deporte-Fety R; Simon N; Fumoleau P; Campone M; Kerbrat P; Bonneterre J; Fargeot P; Urien S
    Cancer Chemother Pharmacol; 2004 Mar; 53(3):233-8. PubMed ID: 14634791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of vinorelbine pharmacokinetics and pharmacodynamics in patients with cancer.
    Wong M; Balleine RL; Blair EY; McLachlan AJ; Ackland SP; Garg MB; Evans S; Farlow D; Collins M; Rivory LP; Hoskins JM; Mann GJ; Clarke CL; Gurney H
    J Clin Oncol; 2006 Jun; 24(16):2448-55. PubMed ID: 16651648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours.
    Trocòniz IF; Garrido MJ; Segura C; Cendrós JM; Principe P; Peraire C; Obach R
    Cancer Chemother Pharmacol; 2006 Jun; 57(6):727-35. PubMed ID: 16261364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aprepitant when added to a standard antiemetic regimen consisting of ondansetron and dexamethasone does not affect vinorelbine pharmacokinetics in cancer patients.
    Loos WJ; de Wit R; Freedman SJ; Van Dyck K; Gambale JJ; Li S; Murphy GM; van Noort C; de Bruijn P; Verweij J
    Cancer Chemother Pharmacol; 2007 Feb; 59(3):407-12. PubMed ID: 17051369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I/II study of pemetrexed and vinorelbine in patients with non-small cell lung cancer.
    Clarke SJ; Boyer MJ; Millward M; Underhill C; Moylan E; Yip D; White S; Childs A; Beale P; Latz J; Suri A; Iglesias JL
    Lung Cancer; 2005 Sep; 49(3):401-12. PubMed ID: 15923057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The clinical pharmacokinetics of vinorelbine (Navelbine).
    Wargin WA; Lucas VS
    Semin Oncol; 1994 Oct; 21(5 Suppl 10):21-7. PubMed ID: 7973765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I and pharmacokinetic study of weekly oral therapy with vinorelbine in patients with advanced breast cancer (ABC).
    Bonneterre J; Chevalier B; Focan C; Mauriac L; Piccart M
    Ann Oncol; 2001 Dec; 12(12):1683-91. PubMed ID: 11843245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral versus intravenous administration of vinorelbine as a single agent for the first-line treatment of metastatic nonsmall cell lung carcinoma (NSCLC): A randomized phase II trial.
    Hirsh V; Desjardins P; Needles BM; Rigas JR; Jahanzeb M; Nguyen L; Zembryki D; Leopold LH
    Am J Clin Oncol; 2007 Jun; 30(3):245-51. PubMed ID: 17551300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors.
    Marty M; Fumoleau P; Adenis A; Rousseau Y; Merrouche Y; Robinet G; Senac I; Puozzo C
    Ann Oncol; 2001 Nov; 12(11):1643-9. PubMed ID: 11822766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study.
    Tedeschi A; Montillo M; Strocchi E; Cafro AM; Tresoldi E; Intropido L; Nichelatti M; Marbello L; Baratè C; Camaggi CM; Morra E
    Cancer Chemother Pharmacol; 2007 May; 59(6):771-9. PubMed ID: 17256136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose escalation of oral vinorelbine in combination with estramustine in hormone-refractory adenocarcinoma of the prostate.
    Mackler NJ; Dunn RL; Hellerstedt B; Cooney KA; Fardig J; Olson K; Pienta KJ; Smith DC
    Cancer; 2006 Jun; 106(12):2617-23. PubMed ID: 16691618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical pharmacokinetics of the antitumor drug navelbine (5'-noranhydrovinblastine).
    Rahmani R; Bruno R; Iliadis A; Favre R; Just S; Barbet J; Cano JP
    Cancer Res; 1987 Nov; 47(21):5796-9. PubMed ID: 3664483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.